Augmedix (OTCMKTS:AUGX) Upgraded by Zacks Investment Research to Buy
Augmedix (OTCMKTS:AUGX – Get Rating) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued to investors on Tuesday, Zacks.com reports. The brokerage currently has a $2.50 target price on the stock. Zacks Investment Research‘s target price points to a potential upside of 23.76% from the […]